Compare YTRA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YTRA | COCH |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | India | United States |
| Employees | N/A | 47 |
| Industry | Transportation Services | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0M | 49.7M |
| IPO Year | 2011 | N/A |
| Metric | YTRA | COCH |
|---|---|---|
| Price | $0.90 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | 28.4K | ★ 125.1K |
| Earning Date | 05-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.36 |
| 52 Week High | $2.00 | $1.89 |
| Indicator | YTRA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 53.20 |
| Support Level | N/A | $0.63 |
| Resistance Level | $1.20 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.32 | 56.07 |
Yatra Online Inc is an Indian consumer travel platform provider and online travel agent. The company is organized into the following business segments; Air Ticketing which derives maximum revenue, Hotels and Packages, and Other Services. It mainly provides travel-related services, which include domestic and international air ticketing, hotel bookings, homestays, holiday packages, bus ticketing, rail ticketing, activities and ancillary services. It also involves hosting advertisements on its internet websites, the sale of rail and bus tickets, and facilitating website access to travel insurance companies. Some of its applications include Yatra Mini, Yatra Web Check-In, Yatra Corporate, and Travelguru HomeStay.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.